Actively Recruiting
Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use
Led by Yale University · Updated on 2025-05-06
40
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
Sponsors
Y
Yale University
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research study is to understand whether concurrent treatment for cigarettes and e-cigarettes in which an individual quits both products at the same time (QUIT-C) or sequential treatment in which an individual quits cigarettes first followed by e-cigarettes is more effective for quitting both products. The study will also compare the effect of treatment on health-related biomarkers. All participants will receive varenicline, a medication used to treat tobacco use dependence, counseling, and cessation resources (i.e., links to text-based support, self-change booklet). Varenicline helps to reduce cravings for tobacco use and decreases the pleasurable effects of cigarettes and other tobacco products.
CONDITIONS
Official Title
Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be literate in English
- Have smoked cigarettes and used e-cigarettes for at least the past 3 months
- Smoke 5 or more cigarettes per day
- Have used e-cigarettes for at least 14 days in the past month
- Be interested in quitting both cigarettes and e-cigarettes within the next month and willing to set a quit date
You will not qualify if you...
- Pregnant women, children, prisoners, or institutionalized individuals
- Participants unable to provide their own consent
- Currently using any smoking cessation services or FDA-approved cessation medications
- Female participants under 55 who are pregnant, breastfeeding, or unwilling to use effective birth control during the study
- Use of other tobacco or nicotine products more than once per week in the last 30 days
- Medical contraindications for varenicline such as severe kidney problems or unstable heart conditions
- Current serious uncontrolled medical or psychiatric conditions requiring recent hospitalization or intensive outpatient treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yale University
New Haven, Connecticut, United States, 06520
Actively Recruiting
Research Team
L
Lisa Fucito, PhD
CONTACT
M
Madilyn Augustine
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here